Evidence map›Paper›PMID 35053575›Full record

ArticleCancers2022

Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment.

Xiaoman Mao, Shuang Wu, Pilar Calero-Pérez, Ana P Candiota, Paula Alfonso, Jordi Bruna, Victor J Yuste, Julia Lorenzo, Fernando Novio, Daniel Ruiz-Molina

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xiaoman MaoCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, Spain.
Shuang WuDepartament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, Spain.
Pilar Calero-PérezDepartament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, Spain.
Ana P CandiotaDepartament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, Spain.ORCID 0000-0002-1523-6505
Paula AlfonsoCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, Spain.ORCID 0000-0002-6554-5656
Jordi BrunaNeuro-Oncology Unit, Bellvitge University Hospital-ICO (IDIBELL), Avinguda de la Gran Via de l'Hospitalet, 199-203, L'Hospitalet de Llobregat, 089098 Barcelona, Spain.ORCID 0000-0001-6895-5047
Victor J YusteInstitut de Neurociències, Departament de Bioquimica i Biologia Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona (UAB), Campus UAB, Cerdanyola del Vallès, 08193 Barcelona, Spain.ORCID 0000-0001-5322-9261
Julia LorenzoDepartament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, Spain.ORCID 0000-0001-5659-6008
Fernando NovioCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, Spain.ORCID 0000-0002-1517-3612
Daniel Ruiz-MolinaCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, Spain.
Universitat Autònoma de Barcelona · ESInstitut Català de Nanociència i Nanotecnologia · ESBellvitge University Hospital · ES

Funding

Autonomous University of Barcelona PIF-19612China Scholarship Council Predoctoral fellowship 201606990027European Cooperation in Science and Technology CA 17140European Council ATTRACT project (Grant Agreement 777222)Ministerio de Ciencia e Innovación (MCIN) PID2020-113058GB-I00Ministerio de Ciencia e Innovación (MCIN) RED2018-102471-TMinisterio de Ciencia e Innovación (MCIN) RTI2018-098027-B-C21Ministerio de Ciencia e Innovación (MCIN) RTI2018-098027-B-C22Ministerio de Ciencia e Innovación (MCIN) SEV-2017-0706
6 · The paper itself

Abstract

Glioblastoma is the most malignant and frequently occurring type of brain tumors in adults. Its treatment has been greatly hampered by the difficulty to achieve effective therapeutic concentration in the tumor sites due to its location and the blood-brain barrier. Intranasal administration has emerged as an alternative for drug delivery into the brain though mucopenetration, and rapid mucociliary clearance still remains an issue to be solved before its implementation. To address these issues, based on the intriguing properties of proteins secreted by mussels, polyphenol and catechol functionalization has already been used to promote mucopenetration, intranasal delivery and transport across the blood-brain barrier. Thus, herein we report the synthesis and study of complex

Indexed as

bioinspiredcatecholglioblastomaintranasalplatinum drugsprodrugPt(IV)

Identifiers

PMID35053575
PMCPMC8774041
OpenAlexW4205659784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.